Kiyotaka Yoh

15PUBLICATIONS
118CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Mar 03, 2025
HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study.

John V Heymach, Frans Opdam, Minal Barve

|Jan 06, 2025
Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study.

Jacob Sands, Myung-Ju Ahn, Aaron Lisberg

|Nov 18, 2024
NETosis in pulmonary pleomorphic carcinoma.

Hajime Oi, Tetsuro Taki, Takashi Kuroe

|Oct 25, 2024
Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY).

Keiju Aokage, Shohei Koyama, Shogo Kumagai

|Jul 18, 2024
PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer.

Fabrice Barlesi, Byoung Chul Cho, Sarah B Goldberg

|May 17, 2024
Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.

Kaname Nosaki, Kiyotaka Yoh, Ryo Toyozawa

Pageof 3

Frequent Collaborators

3 joint publications

Genichiro Ishii

3 joint publications

Koichi Goto

3 joint publications

Yoshitaka Zenke

2 joint publications

Hibiki Udagawa